Browse the evidence

GLP-1 receptor agonist (GLP-1RA) therapy is associated with clinically relevant risks of protein, vitamin, and mineral deficiencies due to reduced caloric and nutrient intake.

If you are taking a GLP-1 medication like semaglutide or tirzepatide, you are likely eating less, which means you might not be getting enough vitamins and minerals. You should prioritize nutrient-dense foods and discuss baseline blood testing for Vitamin D, B12, Iron, and Calcium with your doctor. Do not assume that because this is a medication and not surgery, you are exempt from nutritional monitoring.

GLP-1RA therapy frequently leads to inadequate protein intake, resulting in loss of lean body mass and potential sarcopenia.

To prevent muscle loss while on GLP-1 medication, you must consciously prioritize protein in your diet. Aim for 1.2-2.0 grams of protein per kilogram of body weight daily. If you are struggling to eat enough protein, consider high-protein food choices or supplements, and discuss this with your healthcare provider.

Weight loss interventions (pharmacological or bariatric) in sarcopenic obesity can improve muscle-specific strength and functional parameters despite absolute muscle mass loss, potentially reversing the sarcopenic obesity diagnosis.

If you are considering weight loss medication for obesity, discuss the potential benefits for muscle function. Even if you lose some muscle mass, your strength and ability to function may improve due to reduced fat in muscles and better metabolism. This can reverse sarcopenic obesity.

Shifting focus from weight loss to body recomposition (muscle gain/fat loss) and behavioral goals improves long-term sustainability and psychological outcomes in PCOS.

Do not obsess over the scale. In PCOS, health benefits like better insulin sensitivity and mood come from healthy habits, not just weight loss. Focus on building muscle and moving regularly. This approach is more sustainable and avoids the psychological harm of weight cycling.

The Mediterranean Diet (MedDiet) improves cardiometabolic risk factors, insulin resistance, and hyperandrogenism in PCOS.

Adopt a Mediterranean-style diet: eat plenty of vegetables, fruits, legumes, and whole grains. Use olive oil as your main fat, eat fish and nuts regularly, and limit red meat and processed foods. This pattern helps improve insulin resistance and hormone levels in PCOS.

Vigorous federal, state, and community financial assistance programs during the COVID-19 pandemic significantly improved food security and the healthfulness of food choices for a majority of US adults, particularly among lower-income and minority demographics.

If you are facing food insecurity or struggling to eat healthily during a crisis, prioritize accessing available government assistance programs (like SNAP, emergency food benefits, or community aid). These programs are designed to remove the financial and access barriers that prevent healthy eating, and data shows they can successfully improve both food security and diet quality for vulnerable populations.

Treatment with GLP-1 receptor agonists (semaglutide or dulaglutide) significantly reduces biochemical markers of liver fibrosis (FIB-4 score) and inflammation (De Ritis ratio) in patients with type 2 diabetes and MASLD over 180 days.

For patients with Type 2 Diabetes and fatty liver disease, GLP-1 agonists like semaglutide or dulaglutide (taken weekly) can significantly improve liver health markers (specifically fibrosis risk scores) over 6 months, even without changes to diet or exercise. This suggests these drugs offer liver-specific benefits beyond just weight loss or blood sugar control.

Once-weekly subcutaneous semaglutide (1 mg) produces clinically significant weight loss (median 4.4% in diabetics, 3.4% in non-diabetics) and improves glycemic control (HbA1c reduction of 0.4%) in patients with type 2 diabetes over 6 months.

If you have Type 2 Diabetes, once-weekly semaglutide (starting at 0.25mg and titrating up to 1mg) is a proven tool for losing weight (average ~4-5%) and improving blood sugar control. It works by mimicking a gut hormone to slow digestion and regulate insulin. While nausea is common, it is usually mild. It is not a magic bullet; you still need to eat a balanced diet, but the drug significantly aids the process.

Semaglutide (1 mg) promotes significant weight loss and improves BMI in patients without Type 2 Diabetes, without causing significant changes in HbA1c or hypoglycemia risk.

If you do not have diabetes but struggle with weight, semaglutide (1 mg weekly) can help you lose about 3-4% of your body weight. Because it works based on blood sugar levels, it does not typically cause dangerous low blood sugar (hypoglycemia) in non-diabetics. It is used off-label for this purpose but is supported by clinical guidelines.

Semaglutide improves cardiometabolic risk factors, including diastolic blood pressure, in patients without diabetes, while maintaining renal stability in both diabetic and non-diabetic populations.

Semaglutide offers cardiovascular benefits beyond weight loss, such as lowering diastolic blood pressure in non-diabetics. It also appears to protect kidney function (stable creatinine and albumin/creatinine ratio) in both diabetic and non-diabetic patients, making it a favorable option for those with cardiometabolic risks.

Targeting energy expenditure through thermogenic pathways (such as UCP1, futile creatine, calcium, or lipid cycles) is a viable therapeutic strategy for promoting negative energy balance and sustaining weight loss, distinct from appetite suppression.

While lifestyle changes are foundational, they often fail long-term due to biological counter-regulation. Future treatments may focus on boosting energy expenditure through specific cellular mechanisms (like thermogenesis in fat or muscle) rather than just restricting calories. For now, understanding that your body fights weight loss through increased hunger and reduced expenditure is key to managing expectations.

Consumption of protein supplements by muscle builders significantly alters gut microbiome composition and fecal metabolome, specifically increasing the abundance of Lactobacillales and allantoin while decreasing nucleotide metabolism gene expression compared to non-supplement users.

If you use protein supplements, your gut bacteria and metabolites will look different than non-users, specifically with higher levels of Lactobacillales and allantoin. This is a normal adaptation to higher protein/purine intake and does not imply negative health effects in this population.

Moderate consumption of eggs (1-2 per day) is safe and potentially healthy for most individuals, provided they replace refined carbohydrates or unhealthy meats.

You can safely eat 1-2 eggs per day. They are a healthy source of protein and nutrients. Just make sure you are eating them as part of a balanced diet, not alongside refined carbohydrates or processed meats.

Zinc supplementation (50 mg oral zinc acetate, 2x/day for 14 weeks) improves insulin secretion specifically in individuals with the SLC30A8 rs13266634 CT/TT genotype, demonstrating a genotype-dependent response to micronutrient intervention.

If you are considering zinc supplementation for insulin resistance, check your SLC30A8 genotype first. If you carry the CT or TT variant of rs13266634, 50mg of zinc acetate twice daily for 14 weeks may significantly boost your fasting insulin levels. If you have the CC genotype, this specific intervention may not offer the same benefit.

High adherence to a Mediterranean diet improves inflammatory biomarkers (triglycerides, hsCRP) in individuals with the TNF rs1800629 GG genotype, demonstrating that dietary patterns can modulate genetic inflammation risk.

If you have the TNF rs1800629 GG genotype, you are genetically predisposed to higher inflammation and triglycerides. Adopting a Mediterranean diet for at least one year can significantly improve these markers, reducing your cardiovascular risk. This is a key example of how diet can counteract genetic inflammation.

High dietary protein intake is not detrimental to bone health and may support bone microarchitecture and strength, particularly from animal and dairy sources.

You do not need to limit protein for the sake of your bones. High protein intake, especially from dairy and animal sources, is associated with stronger bone structure. Ensure adequate calcium and vitamin D, but do not fear protein.

Hormonal contraceptive (HC) use is associated with a lower likelihood of experiencing menstrual cycle symptoms, specifically uterine cramps, in resistance-trained athletes.

If you are a resistance-trained athlete experiencing severe menstrual cramps, hormonal contraceptives (particularly combined oral pills) are statistically associated with a reduction in these symptoms. However, be aware that nearly half of users report unwanted side effects from the contraceptives themselves. Consult a healthcare provider to weigh the benefit of reduced cramping against the risk of HC side effects.

Competitive-level resistance-trained athletes are significantly less likely to alter their training load or volume due to menstrual cycle symptoms compared to recreational athletes.

If you are a competitive strength athlete, you are statistically less likely to skip or reduce training due to menstrual symptoms than a recreational lifter. This is likely due to competitive drive. However, be aware that 69.5% of all participants still altered their programs, so monitor your fatigue and load to ensure you are not compromising long-term recovery or health.

Increased physical activity during GLP-1 RA therapy may help attenuate the medication-associated increase in resting heart rate, though this effect was not statistically significant in this study.

If you are experiencing an increased heart rate on GLP-1 medication, try to incorporate more physical activity. This study suggests that higher activity levels might help blunt this increase, although more research is needed to confirm this. Aim for any amount of movement, as even small increases (median split was <10 min/day) showed a trend toward benefit.

Probiotic supplementation has a regulatory effect on weight and BMI, with greater weight loss magnitude observed in populations with longer treatment durations.

If you are considering probiotics for weight management, look for strains with clinical evidence for obesity. The paper notes that longer treatment durations are associated with greater weight loss, suggesting consistency is key. It is not a quick fix but may support metabolic health over time.

Lifestyle interventions (diet and exercise) significantly improve sperm normal morphology and progressive motility in men with obesity, whereas bariatric surgery and pharmacotherapy (metformin/liraglutide) show no clinically significant improvements in semen parameters or DNA damage.

If you are overweight and trying to conceive, focus on sustainable lifestyle changes (diet and exercise) rather than seeking surgical or pharmacological weight loss solutions solely for fertility. Lifestyle changes have been shown to improve sperm morphology and motility, whereas surgery and weight-loss drugs have not shown consistent benefits for semen quality in this population.

Genetic variants in GLP1R (e.g., rs6923761), GIPR (e.g., rs2287019, rs10423928), and TCF7L2 (rs7903146) significantly influence individual response to tirzepatide, affecting glycemic control, weight loss, and side effect profiles.

Your genes can affect how well tirzepatide works for you. If you have certain genetic variants, you might need a different dose or might experience different side effects. Talk to your doctor about genetic testing to personalize your treatment.

Pre-pregnancy lifestyle interventions (dietary restriction or exercise) initiated at least 9 weeks prior to conception reduce the risk of metabolic-associated fatty liver disease (MAFLD) in offspring of obese mothers, whereas interventions initiated only 1 week prior do not.

If you have obesity and plan to conceive, starting weight management 9+ weeks before trying to get pregnant is critical for your future child's liver health. Standard lifestyle changes may take too long, so discuss pre-pregnancy pharmacotherapy (like GLP-1 agonists) with your doctor to ensure you reach a healthy weight before conception.

Pre-pregnancy use of GLP-1 receptor agonists (e.g., liraglutide) or GLP-1/GIP co-agonists (e.g., tirzepatide) is a promising pharmacotherapeutic strategy for pre-pregnancy weight loss in obese women, potentially mitigating the intergenerational risk of MAFLD in offspring, provided sufficient wash-out periods are observed.

If lifestyle changes aren't enough to help you reach a healthy weight before pregnancy, talk to your doctor about GLP-1 medications. They are effective for weight loss and may improve your future child's liver health. Crucially, you must stop these medications well before trying to conceive to ensure they are out of your system.